Ticker brief
SNDX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
21
authors 14d
15
crowd 14d
-0.6σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-12 → 2026-10-15 · now +0.50 (−1 bearish … +1 bullish)
Who spoke15
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 3 | +0.07 |
| @Tickeron | C | +1.53 | 3 | -0.02 |
| @semodough | C | -1.06 | 2 | -0.15 |
| @Briefingcom | B | -2.26 | 2 | -0.50 |
| @zohmbastic | C | -2.94 | 1 | -0.70 |
| @BioStocks | C | -1.77 | 1 | -0.60 |
| @AlertsAndNews | C | -3.92 | 1 | -0.70 |
| @tenet_research | C | -1.23 | 1 | -0.70 |
| @BPharmCatalyst | C | · | 1 | -0.50 |
| @ElliottWaveSage | C | +0.28 | 1 | -0.60 |
| @fwpharma | B | -1.91 | 1 | -0.48 |
| @zerohedge | C | -2.79 | 1 | +0.42 |
| @Omnitrader69 | C | -2.17 | 1 | +0.70 |
| @ClassicRoy | C | -1.10 | 1 | +0.00 |
| @PersimmonTI | A | +0.79 | 1 | +0.90 |
Recent signals21of 21 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @PersimmonTI | +0.90 | Author explicitly expresses extreme bullish enthusiasm for SNDX. | · | tweet ↗ |
| 2026-10-15 | @OzmosiHealth | +0.10 | Syndax's Revuforj was named to TIME's Best Inventions of 2026 list. | · | tweet ↗ |
| 2026-10-13 | @Tickeron | +0.25 | Summarizes nine analyst targets and the upside required after a Phase 2 trial miss. | · | tweet ↗ |
| 2026-10-13 | @OzmosiHealth | +0.10 | Syndax scheduled Phase 3 axatilimab results by year-end 2026. | · | tweet ↗ |
| 2026-10-13 | @ClassicRoy | +0.00 | Ranks names with the largest standard-deviation decline versus 20 days. | · | tweet ↗ |
| 2026-10-13 | @Tickeron | +0.45 | Aggregates eight analyst targets into a $39 central objective implying 135% upside. | · | tweet ↗ |
| 2026-10-13 | @Tickeron | -0.75 | Reports a Phase 2 primary-endpoint miss and discontinuation of axatilimab development in IPF. | · | tweet ↗ |
| 2026-10-13 | @Omnitrader69 | +0.70 | Gradually buying SNDX on the opening pullback with cash freed by FRMI. — Explicit ongoing SNDX accumulation; FRMI is cited as the funding source. | · | tweet ↗ |
| 2026-10-13 | @zerohedge | +0.42 | Premarket roundup links six company moves to analyst actions, earnings, a contract and failed clinical data. | · | tweet ↗ |
| 2026-10-13 | @Briefingcom | -0.60 | Syndax's Phase 2 IPF trial missed its primary endpoint and the company discontinued development. | · | tweet ↗ |
| 2026-10-13 | @Briefingcom | -0.40 | Lists the largest premarket gaps, led by SCNI up 59.5% and SNDX down 10.4%. | · | tweet ↗ |
| 2026-10-13 | @semodough | +0.30 | BofA maintained Buy on Syndax while cutting its target to $23 from $26 and calling the reaction overdone. | · | tweet ↗ |
| 2026-10-13 | @fwpharma | -0.48 | Syndax and Incyte discontinued a lung-fibrosis program after a Phase II miss. | · | tweet ↗ |
| 2026-10-12 | @ElliottWaveSage | -0.60 | Phase 2 trial missed its primary endpoint and the disease program will stop. | · | tweet ↗ |
| 2026-10-12 | @OzmosiHealth | +0.00 | Syndax announced topline Phase 2 trial results without stating their direction. | · | tweet ↗ |
| 2026-10-12 | @BPharmCatalyst | -0.50 | SNDX's Phase 2 axatilimab study missed its primary endpoint, ending the IPF program. | · | tweet ↗ |
| 2026-10-12 | @tenet_research | -0.70 | Reports a Phase 2 axatilimab failure and termination of further IPF development. | · | tweet ↗ |
| 2026-10-12 | @AlertsAndNews | -0.70 | Reports a stock drop after Syndax's Phase 2 trial missed its primary endpoint. | · | tweet ↗ |
| 2026-10-12 | @semodough | -0.60 | Reports axatilimab missing the primary FVC endpoint while noting acceptable safety. | · | tweet ↗ |
| 2026-10-12 | @BioStocks | -0.60 | Phase 2 axatilimab trial failed its primary endpoint. | · | tweet ↗ |
| 2026-10-12 | @zohmbastic | -0.70 | Reports that Syndax's trial failed its primary efficacy endpoint. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.